Zacks Investment Research downgraded shares of Bellerophon Therapeutics (NASDAQ:BLPH) from a buy rating to a hold rating in a research report report published on Friday, Zacks.com reports.

According to Zacks, “Bellerophon Therapeutics LLC is a biotherapeutics company. It is focused on developing products for the treatment of cardiopulmonary and cardiac diseases. The company’s product pipeline consists of INOpulse and BCM which are in different clinical stage. Bellerophon Therapeutics LLC is based in Hampton, New Jersey. “

A number of other research analysts have also weighed in on the stock. Maxim Group set a $3.00 price objective on shares of Bellerophon Therapeutics and gave the company a buy rating in a research note on Monday, April 8th. HC Wainwright reaffirmed a buy rating and issued a $3.00 price objective on shares of Bellerophon Therapeutics in a research note on Tuesday, January 29th. Finally, ValuEngine lowered shares of Bellerophon Therapeutics from a buy rating to a hold rating in a research note on Thursday, December 20th.

Shares of NASDAQ BLPH opened at $0.64 on Friday. The firm has a market cap of $44.96 million, a P/E ratio of -1.88 and a beta of -0.01. Bellerophon Therapeutics has a 12-month low of $0.47 and a 12-month high of $3.30.

Bellerophon Therapeutics (NASDAQ:BLPH) last issued its earnings results on Thursday, March 14th. The biotechnology company reported ($0.02) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.12) by $0.10. On average, analysts predict that Bellerophon Therapeutics will post -0.52 EPS for the current year.

In other Bellerophon Therapeutics news, Director Naseem Amin acquired 571,429 shares of the company’s stock in a transaction on Friday, January 25th. The shares were purchased at an average cost of $0.70 per share, with a total value of $400,000.30. Following the completion of the purchase, the director now owns 1,818,867 shares of the company’s stock, valued at $1,273,206.90. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 53.10% of the stock is currently owned by company insiders.

Several institutional investors have recently added to or reduced their stakes in BLPH. Renaissance Technologies LLC lifted its position in shares of Bellerophon Therapeutics by 4.7% during the third quarter. Renaissance Technologies LLC now owns 1,213,276 shares of the biotechnology company’s stock valued at $1,310,000 after purchasing an additional 54,076 shares in the last quarter. Vanguard Group Inc lifted its position in shares of Bellerophon Therapeutics by 2.5% during the third quarter. Vanguard Group Inc now owns 1,023,533 shares of the biotechnology company’s stock valued at $1,105,000 after purchasing an additional 25,300 shares in the last quarter. Geode Capital Management LLC lifted its position in shares of Bellerophon Therapeutics by 13.1% during the fourth quarter. Geode Capital Management LLC now owns 232,890 shares of the biotechnology company’s stock valued at $186,000 after purchasing an additional 27,027 shares in the last quarter. Finally, Virtu Financial LLC lifted its position in shares of Bellerophon Therapeutics by 60.2% during the fourth quarter. Virtu Financial LLC now owns 36,708 shares of the biotechnology company’s stock valued at $29,000 after purchasing an additional 13,799 shares in the last quarter. 47.63% of the stock is currently owned by hedge funds and other institutional investors.

About Bellerophon Therapeutics

Bellerophon Therapeutics, Inc, a clinical-stage therapeutics company, focuses on the development of products at the intersection of drugs and devices for the treatment of cardiopulmonary diseases. The company offers INOpulse, a pulsatile nitric oxide delivery device, which is in Phase III clinical trials for the treatment of pulmonary arterial hypertension; and has completed Phase II clinical trials to treat pulmonary hypertension associated with chronic obstructive pulmonary diseases and pulmonary hypertension associated with idiopathic pulmonary fibrosis.

Featured Story: How do candlesticks reflect price movement?

Get a free copy of the Zacks research report on Bellerophon Therapeutics (BLPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Bellerophon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellerophon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.